Alopecia Areata
Resource Center

Alopecia areata is a disease that happens when the immune system attacks hair follicles and causes hair loss. While hair can be lost from any part of the body, alopecia areata usually affects the head and face.

What is Alopecia Areata?

Alopecia areata is a chronic, immune-mediated disease in which the body's immune system mistakenly attacks the hair follicles, disrupting the normal hair growth cycle and causing hair loss without permanently damaging the follicle itself. It is a common, clinically heterogeneous condition that affects many racial and ethnic groups and does not carry a strong sex predominance.

Onset may occur at any age, but most patients develop the disease before age 40. Early-onset alopecia areata — in pediatric patients under age 10 — tends to represent a more severe subgroup. Hair loss typically begins as one or more round or oval patches on the scalp, though it can also affect the eyebrows, eyelashes, beard, or other body hair. In some cases, small patches merge into larger ones, and in more extensive presentations, hair loss can eventually involve the entire scalp or body. The disease course is unpredictable: hair often regrows on its own, but many patients experience subsequent episodes of hair loss.

Types of Alopecia Areata

Alopecia areata functions as an umbrella term for several clinical presentations, distinguished largely by the extent and pattern of hair loss:

  • Patchy Alopecia Areata: The most common form, causing one or more distinct, coin-sized, round or oval patches of hair loss on the scalp or elsewhere on the body. Most cases remain patchy, though the condition can progress to more extensive forms.
  • Alopecia Totalis: Results in the loss of all or nearly all scalp hair.
  • Alopecia Universalis: The most severe and rarest form, causing complete or near-complete loss of hair on the scalp, face, and body, including eyebrows and eyelashes.
  • Diffuse Alopecia Areata: Causes sudden, widespread thinning across the scalp rather than the typical patchy pattern. Because it resembles other forms of hair loss, such as telogen effluvium or pattern hair loss, it can be more difficult to diagnose. 
  • Ophiasis: A less common presentation in which hair loss occurs in a band along the sides and back of the scalp. It is generally associated with a less favorable prognosis than other subtypes.

Accurate classification of subtype and extent is important for prognosis and treatment planning, since hair regrowth tends to be more complete in patients with less extensive hair loss, later age of onset, no nail changes, and no family history of the disease.

Risk Factors for Alopecia Areata

A risk factor is any characteristic or exposure that increases the likelihood of developing a disease. While not all individuals with these risk factors will develop alopecia areata, and people without them may still be affected, understanding these factors can inform diagnosis and care.

  • Family History: A family history of alopecia areata is present in some patients and is associated with increased risk and a less favorable prognosis for regrowth.
  • Genetic Factors: Alopecia areata is considered a multifactorial, polygenic disease. Genome-wide association studies have identified more than a dozen susceptibility loci, most involved in immune regulation. Patients with Down syndrome have a notably increased risk of developing the disease.
  • Autoimmune Comorbidities: The disease occurs more frequently in patients with comorbid autoimmune disorders, including thyroid disease, vitiligo, psoriasis, and lupus erythematosus.
  • Atopic Disease: Alopecia areata is also associated with a higher rate of atopic conditions, including hay fever, asthma, and eczema.
  • Age of Onset: The disease can develop at any age, but most patients are diagnosed before age 40. Earlier onset — particularly in children under 10 — is associated with more extensive, severe disease.

Sources: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Cleveland Clinic, National Alopecia Areata Foundation (NAAF), and DermNet

Journal of Managed Care + Specialty Pharmacy Resources
JMCP | Journal of Managed Care Specialty Pharmacy
Free Access | Research Article |

All-cause health care resource utilization and costs among adults with alopecia areata: A retrospective claims database study in the United States

Information on the medical costs involved in the care of people with alopecia areata (AA) is limited, but mounting evidence points to significant financial impact for patients with AA. This study explored health care use and medical costs among commercially insured adults with AA in the United States. Patients with AA face greater all-cause medical and out-of-pocket costs, make more health care outpatient visits, and use more corticosteroids than patients without AA.
JMCP | Journal of Managed Care Specialty Pharmacy
Free Access | Research Article |

Overview of alopecia areata for managed care and payer stakeholders in the United States

Alopecia areata (AA) causes hair loss that can be hard to treat. It can impact the quality of life for adults and children and lead to poor attendance and performance at work or school. People with AA often have related health issues, and costs due to AA can be large. One treatment for AA is now approved for adults in the United States, and others have been shown to work in clinical studies.
JMCP | Journal of Managed Care Specialty Pharmacy
Free Access | Research Article |

Comparing the burden of illness in patients with alopecia areata vs atopic dermatitis in the US population from a payer perspective

Alopecia areata (AA), an autoimmune disease characterized by nonscarring hair loss, had no approved treatments in the US until recently. Limited data exist on the burden of AA compared with other inflammatory skin diseases like atopic dermatitis (AD). This analysis found similar total health care costs between AA and AD, despite patients with AA having fewer comorbidities and less medication use. These results support AA status as an important medical condition like AD.
Additional Resources

Benigno M, Anastassopoulos K, Mostaghimi A, et al. Clinical, Cosmetic, and Investigational Dermatology. 2020 Apr. doi: 10.2147/CCID.S245649.

Wyrwich K W, Kitchen H, Knight S, et al. British Journal of Dermatology. 2020 Oct. doi: 10.1111/bjd.18883.

Lee H, Jae Jung S, Patel A, et al. Journal of the American Academy of Dermatology. 2020 Oct. doi: 10.1016/j.jaad.2019.06.1300.

Meah N, Wall D, York K, et al. Journal of the American Academy of Dermatology. 2021 Jun. doi: 10.1016/j.jaad.2020.09.028.

Minokawa Y, Sawada Y, Nakamura M. International Journal of Molecular Sciences. 2022 Jan. doi: 10.3390/ijms23031038.

Minokawa Y, Sawada Y, Nakamura M. International Journal of Molecular Sciences. 2022 Jan. doi: 10.3390/ijms23031038.

Sarac G A, Nayir T, Yildirim P H, et al. Dermatology Practical & Conceptual. 2023 Apr. doi: 10.5826/dpc.1302a118.

Seol J E, Hong S M, Ahn S W, et al. Skin Research and Technology. doi: 10.1111/srt.13440.

Zaaroura H, Gilding A J, Sibbald C. Autoimmunity Reviews. doi: 10.1016/j.autrev.2023.103339.

Gencebay, G, Askin O, Ayudin O, et al. The International Journal of Trichology. doi: 10.4103/ijt.ijt_48_19.

Alsenaid A, Al-Dhubaibi M S, Alhetheli G, et al. Photodiagnosis and Photodynamic Therapy. doi: 10.1016/j.pdpdt.2023.103510.